News about Drug Discovery & Development

Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan

HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.

Drug Discovery & Development | 31/12/2024 | By Aishwarya |  387

Gerresheimer Announces Tentative Approval of SQ Innovation Lasix ONYU from FDA

Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device.

Drug Discovery & Development | 31/12/2024 | By Aishwarya |  331

Huadong Medicine, SynerK Partners to Jointly Develop Novel siRNA Drug SNK-2726

Huadong Medicine Co., Ltd. and SynerK PharmaTech have partnered to co-develop the siRNA drug SNK-2726, targeting hypertension, with Huadong obtaining exclusive rights for Greater China upon option exercise.

Drug Discovery & Development | 30/12/2024 | By Manvi |  362

Vizuro and DCB Partner to Advance Drug Discovery Precision Medicine with Causal Generative AI

Vizuro LLC and the Development Center for Biotechnology (DCB) have signed an MoU to advance multimodal AI-driven drug discovery and precision medicine, fostering innovation in the biotechnology and pharmaceutical sectors.

Drug Discovery & Development | 27/12/2024 | By Manvi |  389

Axcelead DDP Signs Drug Discovery Service Deal with Astellas for Targeted Protein Degraders

Under the agreement, Axcelead DDP will support Astellas’ targeted protein degrader discovery utilizing DegLeadTM Platform and contribute to the generation of breakthrough new drug candidate compounds.

Drug Discovery & Development | 27/12/2024 | By Aishwarya |  321

Mankind Pharma, Innovent Biologics to Commercialize Sintilimab for Cancer Care

This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.

Drug Discovery & Development | 27/12/2024 | By Aishwarya |  388

Aadi Bioscience Signs Licensing Deal with WUXI and HANGZHOU DAC for Novel ADC Portfolio

Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6).

Drug Discovery & Development | 21/12/2024 | By Aishwarya |  872

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan

QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.

Drug Discovery & Development | 19/12/2024 | By Aishwarya |  313

Glenmark Introduces Lacosamide Oral Solution

Glenmark’s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc.

Drug Discovery & Development | 16/12/2024 | By Aishwarya |  395

Valisure Partners with Picket Pharmaceuticals for Independent Certification of Injectable Drugs

Valisure and Picket Pharmaceuticals discovered their shared mission through their involvement in the End Drug Shortages Alliance (EDSA).

Drug Discovery & Development | 07/12/2024 | By Aishwarya |  198